Citadel Advisors
PYXS icon

Citadel Advisors’s Pyxis Oncology PYXS Stock Holding History

Citadel Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.4K Sell
61,249
-182,340
-75% -$275K ﹤0.01% 12106
2025
Q4 		$280K Sell
243,589
-93,770
-28% -$331K ﹤0.01% 10286
2025
Q3 		$749K Buy
+337,359
New +$486K ﹤0.01% 8181
2024
Q4 		– Sell
-275,951
Closed -$796K – 15213
2024
Q3 		$1.01M Buy
+275,951
New +$966K ﹤0.01% 6845
2024
Q2 		– Sell
-4,109
Closed -$17.3K – 15178
2024
Q1 		$17.5K Sell
4,109
-102,726
-96% -$432K ﹤0.01% 13097
2023
Q4 		$192K Buy
+106,835
New +$183K ﹤0.01% 10016
2023
Q2 		– Sell
-27,129
Closed -$109K – 15062
2023
Q1 		$109K Sell
27,129
-1,535,669
-98% -$3.07M ﹤0.01% 11132
2022
Q4 		$2.09M Buy
1,562,798
+32,013
+2% +$48K ﹤0.01% 5404
2022
Q3 		$3.02M Buy
1,530,785
+9,849
+0.6% +$25.7K ﹤0.01% 4801
2022
Q2 		$3.62M Sell
1,520,936
-1,562
-0.1% -$4.16K ﹤0.01% 4415
2022
Q1 		$6.06M Buy
1,522,498
+881
+0.1% +$6.44K ﹤0.01% 3810
2021
Q4 		$16.5M Buy
+1,521,617
New +$17.4M ﹤0.01% 2273

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's PYXS Position: Q1 2026 in Review

Citadel Advisors reduced its Pyxis Oncology (PYXS) stake by 75% in Q1 2026, selling an estimated $275K and leaving 61,249 shares worth $89.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12106.

Citadel Advisors first reported a position in PYXS in Q4 2021 and has held it in 12 quarters since. The position peaked at $16.5M in Q4 2021. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Citadel Advisors held 61,249 shares of Pyxis Oncology worth $89.4K as of Q1 2026.
  • Citadel Advisors sold 182,340 Pyxis Oncology shares in Q1 2026, an estimated $275K.
  • Pyxis Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12106 holding.
  • Citadel Advisors first reported a position in Pyxis Oncology in Q4 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Pyxis Oncology position peaked at $16.5M in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.